Hepatitis C virus infection, HIV and pain sensitivity in opioid-dependent patients

s / Drug and Alcohol Dependence 146 (2015) e2–e33 e7 did not see amain effect for HIV or an interaction effect. Additional analyses will examine the potential moderating role of markers of HIV disease progression. Financial support: K23 DA-028660, T32 AI-007392. http://dx.doi.org/10.1016/j.drugalcdep.2014.09.699 Predictors of substance use outcomes in mentorship for addiction problems Kathlene Tracy1, Mark Burton1, Matthew Warren1, Deborah Guzman1, Marc Galanter1, Theresa Babuscio2, Charla Nich2 1 Psychiatry, New York University School of Medicine, New York, NY, United States 2 Psychiatry, Yale University School of Medicine, New Haven, CT, United States Aims: We conducted a Stage Ia pilot to develop a new intervention, Mentorship for Addiction Problems (MAP), for individuals with substance use disorders in community treatment programsby pilot/feasibility testing, manual writing, training program development, and adherence/competence measure construction. We examined intervention and participant predictors of substance use outcomes. Methods: TenMentors participated for 6months in a piloting of MAP until 30 Mentees received MAP for 12 weeks. Behavioral and biological measures were conducted at baseline, weekly, monthly, and termination.Aseriesofbivariate regressionswereconducted to determine whether any treatment process or participant variables were associated with substance use outcomes. Results: Intervention Predictors. Mentor group supervision attendance was predictive of Mentee percentage of days abstinent from drugs and alcohol for Mentee weeks in treatment, R2 = .790, F(1, 8) = 30.13, p 3months). The independent variablewas HCV status (uninfected controls; mono-infected HCV+; or co-infected HCV+/HIV+). Chisquare and Kruskal-Willis tests were conducted. Results: The sample included 77 opioid-dependent adults: 23 uninfected controls, 35 HCV+, and 19 HCV+/HIV+. Mean age was 44 (SD±9) years, 48% were female, 32% non-white. Median duration on OAT was 2 years (range 1 month to 10 years), the majority (83%) were treated with buprenorphine. No significant differences were detected across groups for both primary and secondary outcomes. Median cold pain tolerance was 22 (controls) vs. 30 (HCV+) vs. 19 (HCV+/HIV+) s, (p=0.63).No significant effectswere found for cold pain thresholds or wind-up ratio. Chronic pain appearedmore prevalent among HCV+ (82%) compared to HCV+/HIV+ participants (63%) and controls (65%), though differences were not statistically significant (p=0.21). Conclusions: Among opioid dependent adults treated with OAT, we did not detect an association between HCV infection and increased pain sensitivity. Chronic pain may be more common amongHCVmono-infected individuals, however thismerits further investigation. Financial support: This study is supported by NIH/NIDA grant K23DA027367. http://dx.doi.org/10.1016/j.drugalcdep.2014.09.701 Who in the world buys ARVs on the black market? The impact of drug use and ARV diversion on adherence Kiyomi Tsuyuki, Hilary Surratt, Maria A. Levi Minzi, Catherine L. O’Grady Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL, United States Aims: Anti-retroviral (ARV) adherence is the most important predictor of regimen success and HIV viral suppression. HIVpositive drug users are found to have less access to ARV treatment and to initiate treatment at more advanced stages of infection than non-drug users. Recent studies also identify ARV diversion as a factor that may affect ARV adherence in drug users. This study